Our Pipeline Advancing new potential treatments for certain GI diseases affecting millions of patients in need COMPOUND INDICATION PHASE I PHASE II PHASE III APPROVAL linaclotide Partner: IBS-C/FC in pediatrics Complete Complete Complete Status of selected key development programs as of December 1, 2020. Represents ongoing phase of development; does not correspond to completion of a particular phase. Partnering Opportunities As a GI focused, US healthcare company, we are interested in discussing opportunities to collaborate on GI products. We are also seeking partners in territories outside of the US for select current development programs. Please contact us with more details on your area of interest. Partner with Us Our Company Our Values Our Executive Team Our Board of Directors Open Payments and Transparency Our Product Discovery of Linaclotide Report a possible side effect Our Pipeline Partnerships Patients Join Us Open Positions Internships, Co-ops and Fellowships Things You Should Know Investors Events & Presentations Corporate Governance Financial Information Stock Information Investor FAQ Press Releases Investor Contacts Media Contact Us Follow Us Privacy Policy Terms of Use California Privacy Policy Site Map Contact Us Copyright © 2021, Ironwood Pharmaceuticals, Inc. All Rights Reserved LINZESS®, CONSTELLA®, IRONWOOD® and their associated logos are trademarks of Ironwood Pharmaceuticals, Inc. Any other trademarks referred to herein are the property of their respective owners. All rights reserved.